Randomized Trial of Cutting Balloon Compared With High-Pressure Angioplasty for the Treatment of Resistant Pulmonary Artery Stenosis
Summary: Children born with congenital heart disease not uncommonly require cardiac catheterization to treat congenital and acquired malformations such as pulmonary artery stenosis, replacing or complementing surgical techniques. In this study of Cutting Balloons compared with high-pressure balloon angioplasty for resistant pulmonary artery stenosis, we have shown superior efficacy with the Cutting Balloon technology and an equivalent safety profile. This finding has important clinical application for a population with previously untreatable disease. Although few studies have evaluated the performance of devices developed for adults but used in children, in this study, we have demonstrated that some of the unique study design and execution difficulties met in the pediatric population can be overcome. We hope that future studies will continue to rigorously evaluate the performance of devices used to treat children with rare diseases relative to more common adult indications.
Conclusion:
Cutting balloon therapy for pulmonary artery stenosis not responsive to low-pressure balloon is more effective than high-pressure balloon therapy and has an equivalent safety profile. 4 
Characterization of Fractionated Atrial Electrograms Critical for Maintenance of Atrial Fibrillation: A Randomized, Controlled Trial of Ablation Strategies (The CFAE AF Trial)
Summary: The significance of complex fractionated atrial electrograms (CFAE) recorded during atrial fibrillation (AF) is controversial. It is unclear whether ablation of CFAE areas eliminates drivers or simply debulks atrial tissue. We hypothesized that certain CFAE morphologies are more likely to represent areas critical for the maintenance of AF. In this study, the effect of CFAE site ablation on AF cycle length was assessed in 20 patients. CFAE morphologies were graded from 1 (most fractionated) to 5 (normal). The sequence of CFAE ablation was randomized to either from grade 1 to 5, or grade 5 to 1. Ablation at sites with CFAE grades 1, 2, and 4 produced cycle length prolongation more often than at grade 5 sites. The proportion of lesions causing AF cycle length prolongation was unaffected by CFAE amplitude, location, or the order in which CFAE were targeted. These findings indicate that CFAE ablation is not simply atrial debulking. Certain CFAE morphologies are more likely to indicate critical areas for AF. Further study is warranted to determine if selective CFAE ablation can improve efficacy and efficiency of AF ablation.
Conclusions: Targeting CFAE is not simply atrial debulking. Ablating certain grades of CFAE increases AF cycle length suggesting they are more important in maintaining AF. 5 
Left Ventricular Lead Position and Clinical Outcome in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) Trial
Summary: Although cardiac resynchronization therapy is an accepted therapeutic modality for patients with heart failure and conduction disturbances, a significant proportion of patients remain nonresponsive to this treatment. An important determinant of successful cardiac resynchronization therapy for heart failure is the position of the left ventricular (LV) pacing lead. The aim of this study was to analyze the impact of the LV lead position on outcome in patients randomized to cardiac resynchronization therapy-defibrillation in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) study. The LV lead position was assessed in 799 patients by means of coronary venograms and chest x-rays recorded at the time of device implantation. The LV lead location was classified along the short axis into an anterior, lateral, or posterior position and along the long axis into a basal, midventricular, or apical region. The results demonstrate that LV lead location along the short axis (ie, anterior, lateral, or posterior walls) does not influence the primary end points of heart failure hospitalization and all-cause mortality. A midventricular (lateral, anterior, or posterior) position was found in 506 (63%), a basal position in 183 (23%), and an apical position in 110 (14%) patients. The apical lead location compared with leads located in the nonapical position (basal or midventricular region) was associated with a significantly increased risk for heart failure and death (hazard ratioϭ1.72; 95% confidence interval, 1.09 -2.71; Pϭ0.019) after adjustment for the clinical covariates. LV leads positioned in the apical region were associated with an unfavorable outcome, suggesting that this lead location should be avoided in cardiac resynchronization therapy.
Conclusion: LV leads positioned in the apical region were associated with an unfavorable outcome, suggesting that this lead location should be avoided in cardiac resynchronization therapy. 6 Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension: ASA-STAT Summary: Pulmonary arterial hypertension (PAH) is a progressive disease that causes exercise limitation, heart failure, and death. Aspirin and simvastatin have powerful effects on atherosclerosis, but have not been studied in PAH. We performed a randomized, double-blind, placebo-controlled 2ϫ2 factorial clinical trial of aspirin and simvastatin in patients with PAH receiving background therapy at 4 centers. Sixty-five subjects were randomized when the trial was terminated by the Data Safety and Monitoring Board after an interim analysis showed futility in reaching the primary end point for simvastatin. After adjustment for baseline 6-minute walk distance, there was no significant difference in the 6-minute walk distance at 6 months between those given aspirin (nϭ32) or placebo (nϭ33; placebo-corrected difference Ϫ0.5 m [95% confidence interval Ϫ28.4 -27.4 m], Pϭ0.97) or between those given simvastatin (nϭ32) or placebo (nϭ33; placebo-corrected difference Ϫ27.6 m [95% confidence interval Ϫ59.6 -4.3 m], Pϭ0.09). This trial did not show any clinical benefit with the use of aspirin or simvastatin in patients with PAH. Traditional indications for these drugs should guide their use in patients with PAH.
Conclusions: Neither aspirin nor simvastatin had a significant effect on the 6-minute walk distance, although patients randomized to simvastatin tended to have a lower 6-minute walk distance at 6 months. These results do not support the routine treatment of patients with PAH with these medications. 7
Insulin Receptor Substrate 1 Gene Variation Modifies Insulin Resistance Response to Weight-Loss Diets in a 2-Year Randomized Trial: The Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) Trial
Summary: Although recent data from gene-environment interaction analyses provide support for the notion of a personalized nutrition approach, evidence from clinical trials is scarce. Genome-wide association studies have identified common genetic variants in the IRS1 locus associated with insulin resistance and hyperinsulinemia, as well as type 2 diabetes mellitus and coronary heart disease. In a 2-year randomized weight-loss trial, the Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) trial, we genotyped the best associated variant (single nucleotide polymorphism rs2943641) in 738 overweight adults, to examine the modifications of the IRS1 gene variation on the long-term changes in body weight, fasting insulin, and insulin resistance in response to weight-loss diets with different compositions of macronutrients. Our results indicated that participants with the IRS1 rs2943641 CC genotype might obtain more benefits in weight loss and improvement of insulin resistance than those without this genotype in response to a high-carbohydrate/ low-fat diet. Our data may provide novel information for the development of effective dietary intervention strategies based on genetic background in preventing diseases related to obesity and insulin resistance, such as type 2 diabetes mellitus and cardiovascular disease.
Conclusions: Individuals with the IRS1 rs2943641 CC genotype might obtain more benefits in weight loss and improvement of insulin resistance than those without this genotype by choosing a high-carbohydrate and low-fat diet. 8 Summary: Durable surface polymer-based drug-loading technology has been most widely used in the currently available drug-eluting stents (DES). However, durable polymers are considered to be partly responsible for pathological vessel reactions and late adverse clinical events such as very late thrombosis and late angiographic catch-up. The NEVO sirolimus-eluting stent (SES) is a novel cobalt-chromium stent combining sirolimus release from reservoirs with bioabsorbable polymer to reduce spatial and temporal polymer exposure. We assessed the arterial response to the NEVO SES in a randomized, blinded comparison versus the surface-coated TAXUS Liberte paclitaxel-eluting stent (PES) in human native coronary lesions using serial intravascular ultrasound analysis (baseline and 6-month follow-up). The NEVO SES showed significantly less neointimal proliferation (5.5Ϯ11.0% versus 11.5Ϯ9.7%, Pϭ0.02), resulting in less late lumen area loss and smaller maximum cross-sectional narrowing at 6 months. The absolute variability of neointima thickness within each stent was significantly reduced with the NEVO SES compared with the TAXUS Liberté PES, despite focal delivery of drug from reservoirs. In addition, the NEVO SES showed significantly less positive vessel remodeling than the TAXUS Liberté PES. In summary, the current intravascular ultrasound study confirmed significantly greater and more consistent suppression of neointima formation with the NEVO sirolimus-eluting stent compared with the TAXUS Liberté stent up to 6 months. This was associated with greater preservation of vessel wall integrity.
Intravascular Ultrasound Results

Conclusions:
The NEVO SES with focal release of sirolimus from reservoirs achieved significantly greater and more consistent suppression of neointimal hyperplasia than the surface-coated TAXUS Liberté PES. This was associated with less positive remodeling and no increased morphological or morphometric abnormalities surrounding the stent or at the stent margins. 9 Radiofrequency Catheter Ablation and Antiarrhythmic Drug Therapy: A Prospective, Randomized, 4-Year Follow-Up Trial: The APAF Study Summary: Long-term follow-up data for radiofrequency catheter ablation (RFA) of atrial fibrillation (AF) are limited. The present study presents the long-term follow-up of the APAF study. A total of 198 patients with paroxysmal AF were randomly assigned to RFA (99 patients) or antiarrhythmic drugs (AADs) (99 patients). By 4 years, the RFA procedure was repeated because of recurrent arrhythmias in 27.3% of patients, whereas only 12.1% of the AAD group remained in sinus rhythm without ablation. During the follow-up, 87.9% of patients initially randomly assigned to AADs crossed over to RFA because of AAD failure or side effects, and 19 of them had progressed to persistent AF before switching to RFA. In an intentionto-treat analysis, 72.7% of patients in the RFA group and 56.5% in the AAD group were free of recurrent AF/atrial tachycardia (Pϭ0.017). RFA significantly improved quality of life (PϽ0.001), whereas AADs patients showed poorer quality of life before crossing over to RFA. Except for new left atrial tachycardias, there were no serious complications caused by RFA. Thus, our data support the superiority of RFA to AAD therapy during longer-term follow-up in this selected patient population with paroxysmal AF.
Conclusions: With follow-up extended to 4 years after randomly assigned, ablation remains superior to antiarrhythmic drug in these patients with paroxysmal atrial fibrillation. 10 RenalGuard therapy is superior to sodium bicarbonate and N-acetylcysteine in preventing contrast-induced acute kidney injury in high-risk patients. The present study supports that concept that increasing the urine flow rate reduces the toxic effect of contrast media. The RenalGuard system is helpful in guiding the physician in achieving high urine output (Ն300 mL/h) while simultaneously balancing urine output and venous fluid infusion to prevent hypovolemia.
Renal Insufficiency
Conclusion:
RenalGuard therapy is superior to sodium bicarbonate and N-acetylcysteine in preventing contrast-induced acute kidney injury in high-risk patients. 11
Angiographic Disease Progression and Residual Risk of Cardiovascular Events While on Optimal Medical Therapy: Observations From the COURAGE Trial
Summary: Acute coronary syndromes are believed to arise commonly from lesions Ͻ50% diameter stenosis. Prognosis in patients with coronary disease is related to overall atherosclerosis burden. In patients treated with optimal medical therapy, symptoms that developed during follow-up were attributed to progression of lesions originally Ͻ50% diameter stenosis in one third of patients. Lesions Ͻ50% that progressed represented Ͻ4% of all such lesions. In patients treated with optimal medical therapy and percutaneous coronary intervention, lesions originally Ն50% diameter stenosis were responsible for new symptoms in 20% of patients and 68% in optimal medical therapy-only patients. The number of nonrevascularized lesions originally Ն50% diameter stenosis was the only angiographic predictor of myocardial infarction or acute coronary syndrome.
Conclusions: Lesions originally Ͻ50% DS were index lesions in one third of patients referred for symptom-driven repeat angiography, but represented Ͻ4% of all such lesions. Nonrevascularized lesions
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originally Ն50% DS were more often index lesions in optimal medical therapy-only patients, but still represented a minority (Ͻ25%) of all such lesions. These findings underscore the need for improved therapies to arrest plaque progression and reliable strategies for selecting stenoses warranting PCI. 12
Predictors and Implications of Stent Thrombosis in Non-ST-Segment Elevation Acute Coronary Syndromes: The ACUITY Trial
Summary: Predictors and clinical correlates of stent thrombosis have been investigated mainly in patients with stable coronary artery disease. There are scant data on the incidence, predictors, and outcomes of stent thrombosis in patients with non-ST-segment elevation acute coronary syndromes. The present report is the largest study to date to investigate early and late stent thrombosis in patients with moderate and high-risk non-ST-segment elevation acute coronary syndromes. Compared with elective stent implantation, stent thrombosis occurs with increased frequency in the first year after stent implantation in patients with non-ST-segment elevation acute coronary syndromes, especially within the first 30 days. Insulintreated diabetes mellitus, the number of diseased vessels, and dynamic ST-segment changes were independent predictors of stent thrombosis.
Conclusions: Compared with elective stent implantation, stent thrombosis (ST) occurs with increased frequency in the first year after stent implantation in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS), especially within the first 30 days, and is associated with marked increases in cardiac mortality and adverse events. Insulin-treated diabetes, number of diseased vessels, and dynamic ST-segment changes were independent predictors of 1-year ST in NSTE-ACS. 13 
Effect of Dietary Protein Supplementation on Blood Pressure: A Randomized, Controlled Trial
Summary: Observational epidemiological studies have reported an inverse association between dietary protein intake and blood pressure. We compared the effect of soy protein, milk protein, and complex carbohydrate supplementation on blood pressure in a randomized, double-blind crossover trial among 352 adults with prehypertension or stage 1 hypertension. The trial participants were assigned to take 40 g/d of soy protein, milk protein, or complex carbohydrate supplementation each for 8 weeks in a random order. A 3-week washout period was implemented between the interventions. Three blood pressure measurements were obtained at 2 baseline and 2 termination visits during each of the 3 intervention phases by use of a random-zero sphygmomanometer. Compared with carbohydrate controls, soy protein and milk protein supplementations were significantly associated with a Ϫ2.0 mm Hg (95% confidence interval Ϫ3.2 to Ϫ0.7 mm Hg, Pϭ0.002) and Ϫ2.3 mm Hg (Ϫ3.7 to Ϫ1.0 mm Hg, Pϭ0.0007) net change in systolic blood pressure, respectively. The results from this randomized, controlled trial indicate that both soy and milk protein intake reduce systolic blood pressure compared with carbohydrate intake among patients with prehypertension and stage 1 hypertension. Furthermore, these findings suggest that partially replacing carbohydrate with soy or milk protein might be an important component of nutrition intervention strategies for the prevention and treatment of hypertension.
Conclusions:
The results from this randomized, controlled trial indicate that both soy and milk protein intake reduce systolic blood pressure compared with a high-glycemic-index refined carbohydrate among patients with prehypertension and stage 1 hypertension. Furthermore, these findings suggest that partially replacing carbohydrate with soy or milk protein might be an important component of nutrition intervention strategies for the prevention and treatment of hypertension. 14
Novel Approaches for Preventing or Limiting Events in Diabetic Patients (Naples-Diabetes) Trial: A Randomized Comparison of 3 Drug-Eluting Stents in Diabetic Patients
Summary: Diabetic patients with de novo lesions in native coronary arteries were randomly assigned to be treated with sirolimus-eluting stents (Cypher group; nϭ76), paclitaxel-eluting stents (Taxus group; nϭ75), or everolimus-eluting stents (Endeavor group; nϭ75). The primary end point of the study was a composite of major adverse cardiac events (MACE), including death of any cause, myocardial infarction, and clinically driven target vessel revascularization at 3 years. MACE-free survival was found to be 86.8% in the Cypher group, 82.5% in the Taxus group, and 64.4% in the Endeavor group (Pϭ0.006 by log-rank test). Post hoc analysis showed no significant difference between the Cypher and Taxus groups (adjusted, Pϭ1.0), whereas a higher MACE rate was observed in the Endeavor group as compared with the Cypher group (adjusted, Pϭ0.012) and the Taxus group (adjusted, Pϭ0.075). The present pilot study suggests that in diabetic patients, the Endeavor stent is associated with a higher 3-year MACE rate when compared with Cypher or Taxus stents.
Conclusions: The present pilot study suggests that in diabetic patients, the Endeavor stent is associated with a higher 3-year MACE rate when compared with Cypher and Taxus stents. 15 
Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa: The Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Experience
Summary: Although anemia has been associated with higher mortality and morbidity in subjects with diabetes mellitus and nondialysis chronic kidney disease, treatments with erythropoiesisstimulating agents have not led to improvements in prognosis. In the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT), a concerning increase in the risk of darbepoetin alfarelated stroke was observed. We examined the role of baseline predictors and postrandomization factors that might explain this heightened risk of stroke with darbepoetin alfa. We found that in this cohort of patients with type 2 diabetes mellitus, nondialysis chronic kidney disease, and anemia, the risk of stroke related to darbepoetin alfa did not appear to be associated with any baseline characteristic. Despite extensive sensitivity analyses, this risk did not seem to be mediated by postrandomization factors previously implicated as mechanisms of erythropoiesis-stimulating agent-related adverse outcomes, including increase in hemoglobin level, blood pressure, or platelet number, and was not related to dose of darbepoetin alfa. Therefore, clinicians cannot rely on monitoring these readily available follow-up parameters to mitigate the risk of darbepoetin alfa-related stroke.
Conclusions: The 2-fold increase in stroke with darbepoetin alfa in TREAT could not be attributed to any baseline characteristic or to postrandomization blood pressure, hemoglobin, platelet count, or dose of treatment. These readily identifiable factors could not be used to mitigate the risk of darbepoetin alfa-related stroke. 16 
Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Summary: In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor prevented the composite of cardiovascular death, myocardial infarction, and stroke better than clopidogrel in a broad acute coronary syndrome population, without increased risk of overall major bleeding. Preplanned analyses examined variation in the treatment effect in relation to 31 demographic and patient e314 Circulation November 13, 2012 characteristics and found a nominally significant interaction of treatment with region. Clopidogrel was associated with a nonsignificant trend of better outcome in North America, whereas ticagrelor was associated with better outcome in the other regions combined. Lower maintenance doses of aspirin were used in the other regions. Of 37 baseline and postrandomization factors explored with Cox regression and separately with landmark techniques, only aspirin dose explained a substantial fraction of the regional interaction; however, given the limitations of these post hoc analyses, the play of chance remains an alternative explanation. Despite robust statistical techniques, a randomized clinical trial is the definitive approach to understanding the dose of aspirin and outcomes with ticagrelor and clopidogrel. Current guidelines for the management of patients with acute coronary syndromes recommend low-dose maintenance aspirin; during potent P2Y 12 inhibition with ticagrelor in patients with acute coronary syndromes, low-dose maintenance aspirin is associated with favorable outcomes.
Conclusions:
The regional interaction could arise from chance alone.
Results of 2 independently performed analyses identified an underlying statistical interaction with aspirin maintenance dose as a possible explanation for the regional difference. The lowest risk of cardiovascular death, myocardial infarction, or stroke with ticagrelor compared with clopidogrel is associated with a low maintenance dose of concomitant aspirin. 17
Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Summary: Heart failure is the leading cause of hospital admissions among Americans receiving Medicare. Despite advances in treatment, its prognosis remains dismal, with 80% mortality at 10 years. The prevalence is growing, as is the cost (Ͼ$37 billion annually), whereas available Medicare dollars continue to decline. Prevention of heart failure is a life-saving and cost-effective imperative. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), the largest antihypertensive study ever undertaken, was undertaken to compare cardiovascular outcomes among high-risk hypertensive patients randomly assigned to 1 of 3 commonly used antihypertensive medications. ALLHAT provided important and unique advantages to the practicing clinician seeking answers for patient care, including (1) its clinics and their patients were community-based; (2) its population reflected ethnic, racial, and sex diversity; (3) its outcomes were clinical rather than surrogate; and (4) its participants' time on study was long-term, with an average of nearly 5 years active and 4 years passive follow-up. The results of ALLHAT showed that properly dosed diuretics, best in prevention of heart failure, should be part of the antihypertensive treatment regimen. Through long-term observation of this uniquely large cohort, we confirm that once heart failure develops, the antihypertensive treatment regimen matters little. Prevention of heart failure is paramount not only for patient health, but also for the public health, and adequate treatment and control of blood pressure in hypertensive patients is a necessary prerequisite to heart failure prevention.
Conclusions: Once heart failure (HF) develops, risk of death is high and consistent across randomized treatment groups. Measures to prevent the development of HF, especially blood pressure control, must be a priority if mortality associated with the development of HF is to be addressed. 18 showed that cardiac resynchronization-defibrillator therapy is associated with a significant reduction in the risk of heart failure or death compared with defibrillator-only therapy. Currently, however, there is limited information on the factors that can be used to distinguish between responders and nonresponders in this population. In the present study, we developed a response score that was based on 7 factors we identified as being associated with favorable reverse remodeling in MADIT-CRT: female sex, a nonischemic origin of cardiomyopathy, left bundle-branch block, QRS Ն150 milliseconds, prior hospitalization for heart failure, left ventricular end-diastolic volume Ն125 mL/m 2 , and left atrial volume Ͻ40 mL/m 2 . The score was then used to assess the clinical benefit of cardiac resynchronization-defibrillator therapy during the trial. We show a direct correlation between an increasing response score and the magnitude of the reduction in the risk of heart failure or death with cardiac resynchronization therapy. There was a significant 13% increase in the clinical benefit of cardiac resynchronizationdefibrillator therapy per 1-point increment in the response score and a significant direct correlation between risk reduction associated with cardiac resynchronization-defibrillator therapy and response score quartiles. Thus, our findings suggest that combined assessment of factors associated with reverse remodeling can be used for improved selection of patients for cardiac resynchronization therapy.
Predictors of Response to Cardiac
Conclusion:
Combined assessment of factors associated with reverse remodeling can be used for improved selection of patients for cardiac resynchronization therapy. 19 
Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca
2؉ -ATPase in Patients With Advanced Heart Failure
Summary: The Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) phase 2 randomized, double-blind trial evaluated adeno-associated virus type 1 (AAV1)/sarcoplasmic reticulum Ca 2ϩ -ATPase (SERCA2a) versus placebo in 39 patients. A deficiency in SERCA2a has been identified in cardiomyocytes from failing human hearts. AAV1/SERCA2a is a viral vector delivering the deficient SERCA2a gene by intracoronary infusion into patients with advanced heart failure. AAV1/SERCA2a in this study population demonstrated no untoward safety findings; there appeared to be fewer cardiovascular adverse events in the high-dose group compared with placebo. The study met the prospectively defined efficacy end points comprising 7 different parameters in 5 clinically relevant domains. All 3 predefined analyses were met at the individual-level, group-level (in functional and left ventricular function/remodeling domains), and clinical outcomes (duration of cardiovascular hospitalizations). High-dose AAV1/SERCA2a compared with placebo also demonstrated significantly delayed and reduced frequency of adverse cardiovascular events per patient, reaching statistical significance at 12 months (Pϭ0.003). The positive signals across 5 domains support the contention that high-dose AAV1/SERCA2a induced meaningful biological activity. Results from this small study indicate a decrease in symptoms of heart failure, augmented functional status, a decrease in natriuretic peptide levels, beneficial ventricular reverse remodeling, and a significant increase in time to and decreased frequency of adjudicated cardiovascular events in the high-dose group versus placebo. The totality of the data, limited by the small study size, strongly supports moving forward with confirmatory clinical studies of AAV1/SERCA2a for patients with severe heart failure. This CUPID trial represents a new approach to the treatment of heart failure with enzyme replacement via gene therapy.
Conclusions:
The Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) study demonstrated safety and suggested benefit of adeno-associated virus type
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1/sarcoplasmic reticulum Ca 2ϩ -ATPase in advanced heart failure, supporting larger confirmatory trials. 20 
Predictors of Bleeding and Time Dependence of Association of Bleeding With Mortality: Insights From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38)
Summary: Several recent studies have shown that intensified dual antiplatelet therapy can reduce the risk of major cardiovascular events in patients with acute coronary syndromes, but with an increase in bleeding. The balance between benefit (prevention of ischemic events) and risk (significant bleeding) is therefore a key consideration in choosing the intensity of antiplatelet therapy. This analysis of the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38), which compared prasugrel to standard-dose clopidogrel in patients with acute coronary syndromes undergoing a planned percutaneous coronary intervention, showed that the most common types of serious bleeding were gastrointestinal and vascular access site bleeding. Variables most strongly associated with risk of serious bleeding were female sex, use of a glycoprotein IIb/IIIa inhibitor, duration of intervention, age, assignment to prasugrel, ST-elevation myocardial infarction, femoral access for angiography, creatinine clearance, hypercholesterolemia, and hypertension. Serious bleeding was significantly associated with mortality after correction for these factors. Analyses focusing on the time dependency of this relationship showed that this association existed only for the first week after an instrumented or traumatic bleeding event. After a spontaneous serious bleeding event, bleeding was significantly associated with mortality for Ϸ40 days. There did not appear to be a prolonged hazard beyond these time periods.
Conclusion:
The major predictors of serious bleeding were a combination of patient and procedural characteristics and antiplatelet therapies. Although serious bleeding was strongly associated with mortality within the first month of the bleeding event, this association was not significant beyond 40 days. 21 
Myocardial Infarction After Carotid Stenting and Endarterectomy: Results From the Carotid Revascularization Endarterectomy Versus Stenting Trial
Summary: The Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) showed no difference in the composite end point of stroke, myocardial infarction (MI), or death during the periprocedural period and ipsilateral stroke during follow-up. The higher risk of stroke with carotid artery stenting and higher risk of periprocedural myocardial infarction after carotid endarterectomy underscore the need for detailed analysis of the MI end point. Among 2502 patients, 14 MIs occurred in carotid artery stenting and 28 MIs in carotid endarterectomy (hazard ratio, 0.50; 95% confidence interval, 0.26 -0.94; Pϭ0.032), with a median biomarker ratio of 40 times the upper limit of normal. An additional 8 carotid artery stenting and 12 carotid endarterectomy patients had biomarker positivity only (hazard ratio, 0.66; 95% confidence interval, 0.27-1.61; Pϭ0.36), and their median biomarker ratio was 14 times the upper limit of normal. Compared with patients without biomarker elevation, mortality was higher over 4 years for those with MI (hazard ratio, 3.40; 95% confidence interval, 1.67-6.92) or biomarker positivity only (hazard ratio, 3.57; 95% confidence interval, 1.46 -8.68). After adjustment for baseline risk factors, both MI and biomarker positivity only remained independently associated with increased mortality. In the randomized CREST trial, both MI and biomarker positivity without symptoms or ECG changes were more common with carotid endarterectomy than carotid artery stenting. Both events were associated with increased long-term mortality in unadjusted and risk-adjusted analyses, suggesting that the occurrence of periprocedural MI or biomarker positivity only identifies a population of patients at greater risk of death in longer-term follow-up. The findings also suggest that individualized patient risk for such events may be an important consideration in the choice of carotid artery stenting or carotid endarterectomy and the choice of carotid revascularization or medical therapy.
Conclusions:
In patients randomized to carotid endarterectomy versus carotid artery stenting, both MI and biomarkerϩ only were more common with carotid endarterectomy. Although the levels of biomarker elevation were modest, both events were independently associated with increased future mortality and remain an important consideration in choosing the mode of carotid revascularization or medical therapy. 22 
Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT)
Summary: There is an increasing interest and need to identify heart failure patients who benefit from cardiac resynchronization therapy (CRT), as well as those who do not. In patients with a wide QRS complex who qualify for CRT, QRS morphology indicates different conduction delays, represented on the ECG as left bundle-branch block (LBBB), right bundle-brunch block (RBBB), or nonspecific intraventricular conduction disturbances. The Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) demonstrated that in patients with mild to moderate heart failure, CRT with defibrillator implantation (CRT-D) significantly reduced the risk of heart failure events or death compared with treatment with only an implantable cardioverter-defibrillator. This analysis of the MADIT-CRT trial data demonstrated that compared with non-LBBB patients (those with RBBB or nonspecific intraventricular conduction disturbances), patients with LBBB QRS morphology showed significant clinical benefit from CRT-D therapy, as measured by reduced risk of heart failure event or death and risk of ventricular tachycardia/fibrillation or death. Non-LBBB patients did not benefit clinically despite a significant reduction in left ventricular volumes. These findings formed the basis for recent Food and Drug Administration approval of new broadened indications for CRT in mild or asymptomatic heart failure patients with LBBB. There is still a question as to whether CRT therapy should be used in non-LBBB patients even when advanced heart failure is present and which non-LBBB patients might still benefit clinically from CRT. Further research investigating the rationale, mechanisms, and clinical benefit is needed to determine whether CRT therapy should be pursued in non-LBBB patients.
Conclusions: Heart failure patients with New York Heart Association class I or II and ejection fraction Յ30% and LBBB derive substantial clinical benefit from CRT-D: a reduction in heart failure progression and a reduction in the risk of ventricular tachyarrhythmias. No clinical benefit was observed in patients with a non-LBBB QRS pattern (right bundle-branch block or intraventricular conduction disturbances). 23 
Efficacy of Quantified Home-Based Exercise and Supervised Exercise in Patients With Intermittent Claudication: A Randomized Controlled Trial
Summary: A primary therapeutic goal for patients with peripheral artery disease and intermittent claudication is to regain lost ambulatory function through exercise rehabilitation. Medically supervised e316 Circulation November 13, 2012 exercise programs are efficacious for improving claudication onset time and peak walking time, but more patients could benefit from an exercise program transported to the community setting (ie, homebased walking). However, home exercise has been poorly studied. This prospective, randomized, controlled clinical trial compared changes in claudication onset time, peak walking time, and daily ambulatory activity in peripheral artery disease patients with intermittent claudication after home-based exercise, supervised exercise, and usual-care control. Both exercise programs consisted of intermittent walking to near-maximal claudication pain for 12 weeks. We used a step activity monitor to address the primary flaw of previous home exercise programs by objectively measuring ambulatory cadence during home exercise sessions. Patients in home-based exercise completed 83% of their exercise sessions, averaging 42 minutes per session at a cadence of 37 strides per minute, and they increased claudication onset time, peak walking time, and daily ambulatory cadences apart from the exercise sessions. The changes in claudication onset time and peak walking time after home-based exercise were similar to those after supervised exercise, whereas the change in daily ambulatory cadences was greater. The clinical implication is that a home-based exercise program consisting of ambulatory monitoring, biweekly 15-minute meetings with staff, and feedback motivated patients to adhere to the program and may serve as a new model for improving claudication measures in more patients with less effort and fewer resources than a traditional supervised exercise program.
Conclusions: A home-based exercise program, quantified with a step activity monitor, has high adherence and is efficacious in improving claudication measures similar to a standard supervised exercise program. Furthermore, home-based exercise appears more efficacious in increasing daily ambulatory activity in the community setting than supervised exercise. 24
Effects of Hydration in Contrast-Induced Acute Kidney Injury After Primary Angioplasty: A Randomized, Controlled Trial
Summary: Contrast-induced acute kidney injury (CI-AKI) is a significant cause of iatrogenic renal dysfunction, contributing to morbidity, prolonged hospitalization, mortality, and increased costs of health care. The routine use of hydration protocol before contrast exposure is an established preventive measure, recommended in the guidelines against CI-AKI in all elective angiographic procedures involving administration of iodine contrast medium. However, the efficacy of this preventive strategy has not yet been established for patients with ST-elevation-myocardial infarction who are at higher risk of this complication after primary percutaneous coronary intervention. This prospective, randomized study shows that also among patients with acute myocardial infarction treated with primary percutaneous coronary intervention, intravenous volume expansion is beneficial against CI-AKI development. In particular, the regimen of early hydration with sodium bicarbonate significantly reduces the rate of CI-AKI compared with a regimen of only late hydration with saline or no hydration treatment. Early infusion guarantees a larger quantity of fluids than postprocedural hydration, and the amount of fluids administered plays an important role in this setting: multivariate analysis identifies a total hydration volume of Յ960 mL as one of the independent predictors of CI-AKI. Our findings suggest that routine procedure for patients with ST-elevation-myocardial infarction candidates to primary percutaneous coronary intervention should include standard pharmacological treatment associated with early hydration protocol, dosed according to patient weight and baseline ejection fraction, and started in the emergency room whenever feasible. Summary: This randomized controlled trial rigorously tests, on a national scale, whether low-intensity continuous quality improvement interventions can be used to speed secondary prevention adherence after coronary artery bypass graft surgery. A total of 458 hospitals participating in the Society of Thoracic Surgeons National Cardiac Database and treating 361 328 patients undergoing isolated coronary artery bypass graft surgery were randomized to either a control or an intervention group. The intervention group received continuous quality improvement materials designed to influence the prescription of the secondary prevention medications at discharge. The primary outcome measure of the study was discharge prescription rates of the targeted secondary prevention medications at intervention versus control sites, assessed by measuring preintervention and postintervention site differences. Prerandomization treatment patterns and baseline data were similar in the control (nϭ234) and treatment (nϭ224) groups. Individual medication use and composite adherence increased over 24 months in both groups, with a markedly more rapid rate of adherence uptake among the intervention hospitals and a statistically significant therapy hazard ratio in the intervention versus control group for all recommended secondary prevention medications. Thus, we conclude that provider-led, lowintensity continuous quality improvement efforts can improve the adoption of clinical care processes into national practice within the context of a medical specialty society infrastructure. The findings of the present trial have led to the incorporation of study outcome metrics into a medical society rating system for ongoing quality improvement.
Conclusions: Provider-led, low-intensity continuous quality improvement efforts can improve the adoption of care processes into national practice within the context of a medical specialty society infrastructure. The findings of the present trial have led to the incorporation of study outcome metrics into a medical society rating system for ongoing quality improvement. Summary: A growing body of literature links aldosterone to the development and/or progression of a variety of cardiovascular disease processes, including endothelial dysfunction, hypertension, ventricular remodeling, and congestive heart failure. Blockade of the mineralocorticoid receptor with antagonists such as spironolactone has shown benefit in blunting or reversing many of the unfavorable effects attributed to aldosterone. An alternative approach to blocking the effects of aldosterone is to prevent its production by inhibiting aldosterone synthase. The present findings indicate that inhibition of aldosterone synthase with the novel compound LCI699 significantly lowers blood pressure in patients with mild to moderate hypertension. The compound was safe and well tolerated. Aldosterone synthase inhibition with LCI699 was accompanied by suppression of adrenocorticotropic hormone-stimulated release of cortisol in a proportion of subjects, indicating partial inhibition of 11-␤-hydroxylase. Overall, the present results indicate that aldosterone synthase inhibition may represent a novel and effective approach to lowering high blood pressure. Additional studies are needed to determine whether there is differential antihypertensive and/or cardiovascular benefit of suppressing aldosterone production compared with blocking activation of the mineralocorticoid receptor. Such testing will need to include elucidation of the effects of partial suppression of cortisol synthesis.
Conclusions: Aldosterone synthase inhibition with LCI699 significantly lowered clinic and ambulatory blood pressure. A minority of subjects developed blunted adrenocorticotropic hormone-stimulated release of cortisol. These results support additional research to evaluate use of aldosterone synthase inhibition in primary hypertension and/or patients characterized by aldosterone excess. 28 
Cardiac Resynchronization Therapy Reduces the Risk of Cardiac Events in Patients With Diabetes Enrolled in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT)
Summary: Cardiac resynchronization therapy has been shown to reduce the risk of death or heart failure in patients with New York Heart Association class III or IV heart failure. The Multicenter Automatic Defibrillator Implantation Trial: Cardiac Resynchronization Therapy (MADIT-CRT) study extended these results to patients with class I and II heart failure. In this diabetes substudy of MADIT-CRT, we observed that patients with diabetes exhibited more indices of adverse prognosis and had significantly more end point events than those without diabetes. The results of the present study show that pleomorphism (PL) and multiple morphologies (MM) of ventricular tachycardia (VT), as judged by implantable cardioverter-defribillator (ICD) electrograms, are not uncommon findings in patients with ICDs, occurring in 6% and 19%, respectively. Total mortality (5%) was significantly higher in patients with PL (20%), patients with MM (11.5%), and in women (12%). In this prospective series of patients with ICDs, mostly indicated for secondary prevention, PL and MM were strongly associated and predicted all-cause mortality in univariate analysis. PL also was associated with a significantly higher cardiac mortality and with a nonsignificantly higher incidence of arrhythmic death. In multivariate regression analysis, PL, but not MM, was identified as a strong and independent predictor of total mortality, with a Ͼ5-fold increase in the chance of death. This finding affected outcome over the short term because time from the development of PL VT to death (median, 1.5 months; interquartile range, 1.4 -4.9 months) was markedly short compared to time from ICD intervention to the occurrence of PL (median, 6.9 months; interquartile range, 3.6 -11.1 month). In addition to the development of PL VT, female sex independently predicted all-cause mortality. These findings suggest that PL merits further attention as a prognostic determinant in patients with ICDs and recurrent VT. If further studies confirm the ominous short-term prognostic significance of PL VT, more-aggressive approaches, such as catheter ablation, should be explored in an attempt to improve prognosis in this patient population.
Conclusions: In a prospective series of patients with ICDs, mostly indicated for secondary prevention, both PL and MM of VT, as judged by ICD-EG, were not uncommon and were strongly associated. Female sex and the development of PL VT were the only independent predictors of mortality. Summary: Injection of autologous bone marrow-derived mononuclear cells (BM-MNC) is a promising therapeutic option in patients with critical limb ischemia, but double-blind, randomized trials are lacking. The present study is the first randomized, placebo controlled trial showing that intraarterial BM-MNC administration accelerates wound healing and induces pain reduction until 3 months in patients with critical limb ischemia with stable ulcers but not in patients with extensive gangrene. Ulcer healing induced by repeated BM-MNC administration significantly correlated with limb salvage. Successful ulcer healing required repeated applications of functionally competent BM-MNC. These exploratory findings of this pilot trial need to be confirmed in a larger randomized trial in patients with critical limb ischemia and stable ulcers.
Conclusions: Intraarterial administration of BM-MNC is safe and feasible and accelerates wound healing in patients without extensive gangrene and impending amputation. These exploratory findings of this pilot trial need to be confirmed in a larger randomized trial in patients with critical limb ischemia and stable ulcers. 31 
